Table 6.
Comparison of imaging and laboratory test results between symptomatic and asymptomatic patients.
| Symptomatic group (n = 372) | Asymptomatic group (n = 205) | P value | |
|---|---|---|---|
| US evaluable patients, n | 232 | 149 | |
| Detection of abnormal findings, n (%) | 211 (90.9) | 130 (87.2) | 0.25 |
| Pancreatic tumors, n (%) | 195 (84.1) | 92 (61.7) | < 0.001 |
| Indirect findings, n (%) | 154 (66.4) | 112 (75.2) | 0.07 |
| MPD cut-off, n (%) | 115 (49.6) | 69 (46.3) | 0.53 |
| MPD dilatation, n (%) | 133 (57.3) | 97 (65.1) | 0.13 |
| Pancreatic cysts, n (%) | 45 (19.4) | 37 (24.8) | 0.21 |
| CT evaluable patients, n | 365 | 200 | |
| Detection of abnormal findings, n (%) | 364 (99.7) | 200 (100) | 0.46 |
| Pancreatic tumors, n (%) | 356 (97.5) | 178 (89.0) | < 0.001 |
| Indirect findings, n (%) | 304 (83.3) | 173 (87.0) | 0.31 |
| MPD cut-off, n (%) | 263 (72.1) | 155 (77.5) | 0.16 |
| MPD dilatation, n (%) | 254 (69.6) | 156 (78.0) | 0.032 |
| Pancreatic cysts, n (%) | 142 (38.9) | 57 (28.5) | 0.013 |
| MRI evaluable patients, n | 319 | 194 | |
| Detection of abnormal findings, n (%) | 318 (99.7) | 193 (99.5) | 0.72 |
| Pancreatic tumors, n (%) | 299 (93.7) | 149 (76.8) | < 0.001 |
| Indirect findings, n (%) | 280 (87.8) | 179 (92.3) | 0.11 |
| MPD cut-off, n (%) | 240 (75.2) | 155 (79.9) | 0.22 |
| MPD dilatation, n (%) | 232 (72.7) | 157 (80.9) | 0.035 |
| Pancreatic cysts, n (%) | 158 (49.5) | 93 (47.9) | 0.73 |
| EUS evaluable patients, n | 344 | 203 | |
| Detection of abnormal findings, n (%) | 344 (100) | 203 (100) | N/A |
| Pancreatic tumors, n (%) | 339 (98.5) | 193 (95.1) | 0.016 |
| Indirect findings, n (%) | 280 (81.4) | 173 (85.2) | 0.25 |
| MPD cut-off, n (%) | 240 (69.8) | 152 (74.9) | 0.20 |
| MPD dilatation, n (%) | 236 (68.6) | 156 (76.8) | 0.039 |
| Pancreatic cysts, n (%) | 142 (41.3) | 68 (33.5) | 0.07 |
| Laboratory test evaluable patients, n | 372 | 205 | |
| Elevated tumor markers, n (%) | 320 (86.0) | 137 (66.8) | < 0.001 |
| CEA, n (%) | 154 (41.4) | 56 (27.3) | < 0.001 |
| CA19-9, n (%) | 290 (78.0) | 123 (60.0) | < 0.001 |
| Abnormalities of pancreatic enzymes, n (%) | 224 (60.2) | 105 (51.2) | 0.037 |
| Elevated amylase, n (%) | 49 (13.2) | 34 (16.6) | 0.26 |
| Decreased amylase, n (%) | 68 (18.3) | 24 (11.7) | 0.039 |
| Elevated lipase, n (%) | 155 (41.7) | 80 (39.0) | 0.54 |
| Decreased lipase, n (%) | 7 (1.9) | 4 (2.0) | 0.95 |
US ultrasonography, CT computed tomography, MRI magnetic resonance imaging, EUS endoscopic ultrasonography, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, N/A not available.